AstraZeneca (NYSE: AZN) announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults with Major Depressive Disorder (MDD)…
Popularity: 1% [?]
Related posts:
- US FDA Approves SEROQUEL XR(R) For Add-On Treatment Of Major Depressive Disorder
- U.S. Food And Drug Administration Approves ABILIFY(R) (aripiprazole) As The First Medication For Add-On Treatment Of Major Depressive Disorder (MDD)
- FDA Approves Cymbalta® For Maintenance Treatment Of Major Depressive Disorder
- FDA Approves Cymbalta(R) For Maintenance Treatment Of Major Depressive Disorder
- Astrazeneca Submits Seroquel XR™ In Europe For The Treatment Of Major Depressive Disorder
Comments
No Responses to “US FDA Approves SEROQUEL XR(R) For Add-On Treatment Of Major Depressive Disorder”